Regeneron Pharmaceuticals

This is an early-stage study testing the safety of an experimental drug called ALN-ANG3 in healthy adults who have high cholesterol and triglyceride levels. The main goal is to see what side effects might occur and how the drug moves through the body. The study will involve 59 pa…

This study aimed to see if using the approved eczema medication dupilumab could help children with severe eczema grow better and develop stronger bones. It planned to look at children aged 6 to 12 whose eczema was not well-controlled with standard creams. The study was withdrawn …

This study is testing whether a new two-drug immunotherapy combination works better than the current standard single-drug treatment for patients with high-risk melanoma that can be surgically removed. About 151 participants will receive the drugs before their surgery, and can con…

This early-stage study is testing the safety and side effects of a combination of two new drugs, odronextamab and cemiplimab, in patients with aggressive B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The main goal is to find a safe dose …

This program provides continued access to the experimental drug garetosmab for approximately 55 adults worldwide with Fibrodysplasia Ossificans Progressiva (FOP), a rare and debilitating condition where muscles and connective tissues turn into bone. Participants must have complet…

This study is testing an existing drug, dupilumab, to see if it can help people with eosinophilic gastritis, a chronic allergic condition where too many white blood cells cause painful stomach inflammation. The trial will enroll 22 adults and adolescents to receive the drug for u…

This program provides continued access to an experimental two-drug combination (pozelimab and cemdisiran) for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare disease where the immune system destroys red blood cells. It's specifically for patients who have already co…

This program provides compassionate access to the immunotherapy drug cemiplimab for patients with advanced non-small cell lung cancer, basal cell carcinoma, or cutaneous squamous cell carcinoma. It's designed for individuals who have exhausted all other approved treatment options…

This program provides access to an experimental drug called pozelimab for patients with CHAPLE disease, a rare and potentially life-threatening immune disorder that usually appears in childhood. The main goal is to document the long-term safety of the treatment in these patients.…

This study is testing whether adding a new drug called fianlimab to a standard treatment (cemiplimab + chemotherapy) works better for people with advanced non-small cell lung cancer (NSCLC). It will involve about 950 patients who have not yet received treatment for their advanced…

This was a compassionate use program, which allowed continued access to an investigational drug called vidutolimod for patients with melanoma that had stopped responding to other treatments. It was only available to a very specific group of people who had already been receiving t…

This study is testing an experimental antibody drug called REGN7544 in hospitalized adults with sepsis (a severe body-wide infection) who have developed dangerously low blood pressure that isn't responding well to standard treatments. The research aims to see if the drug can help…

This study is testing the safety of switching patients with a rare disorder called generalized lipodystrophy from their current medication to an experimental new drug called mibavademab. It involves a small group of 9 participants who have been stable on their current treatment. …

This program provides access to an investigational drug called REGN5458 for patients with advanced multiple myeloma who have exhausted all approved treatments. It is a 'compassionate use' program, meaning it is for individual patients in urgent need, not a formal clinical trial. …

This Phase 3 trial is testing an experimental drug called garetosmab in adults with fibrodysplasia ossificans progressiva (FOP), a rare disease that causes soft tissues to turn into bone. The main goals are to see if the drug is safe and if it can reduce the number of new abnorma…

This study is testing whether a drug called cemiplimab can prevent a serious type of skin cancer from returning after initial treatment. It involves 415 people with high-risk cutaneous squamous cell carcinoma who have already had surgery and radiation. Participants receive either…

This program provides special access to an investigational drug called pozelimab for patients with a rare, severe digestive disorder known as CD55-deficient protein-losing enteropathy. It is not a standard clinical trial but a pathway for individual patients to request the drug w…

This early-stage study is testing the safety and how the body processes two immunotherapy drugs, cemiplimab and fianlimab, in Japanese patients with advanced lung cancer. The goal is to see if these drugs, alone or combined with chemotherapy, can help the patient's own immune sys…

This study is testing an experimental drug called odronextamab in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goals are to see how well the drug shrinks tumors and to understand its safety. Researchers are …

This large, late-stage trial is comparing a new two-drug combination (fianlimab + cemiplimab) against the current standard treatment (pembrolizumab) for people with advanced melanoma that cannot be removed by surgery. The main goal is to see if the new combination helps patients …

This large, late-stage study is comparing a new two-part drug called odronextamab combined with standard chemotherapy against the current standard treatment (rituximab + chemo) for people newly diagnosed with an aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL)…

This program provides access to dupilumab medication for patients with severe type 2 inflammatory disorders who have no other treatment options. It's designed for compassionate use when standard treatments have failed. Access is granted through individual patient requests and dep…

This study is testing a higher dose of an existing eye injection medicine (aflibercept 8 mg) for people with wet age-related macular degeneration (AMD) or diabetic macular edema (DME). It aims to see if this higher dose is safe and effective when given as often as once a month. T…

This study is testing two new drugs, pozelimab and cemdisiran, to see if they can better control the muscle weakness and fatigue caused by generalized myasthenia gravis (gMG). It will involve about 288 adults with gMG to compare the effectiveness and safety of using the drugs tog…

This study is testing whether adding one or two new experimental drugs to the approved medication Wegovy (semaglutide) can help people with obesity lose more weight and body fat. It involves over 1,000 participants and will first check the safety of the new drugs in healthy volun…

This study is testing whether adding an experimental drug called fianlimab to a standard treatment (cemiplimab plus chemotherapy) is more effective for people with early-stage, operable non-small cell lung cancer. The treatment is given before and after surgery. The main goal is …

This program provides special access to the drug evinacumab for patients with rare, severe inherited cholesterol or triglyceride disorders who have no other treatment options. It is for compassionate use, meaning it is considered on a case-by-case basis for individual patients wh…

This large clinical trial is testing whether adding a new immunotherapy drug (fianlimab) to an existing one (cemiplimab) works better than the single drug alone for people with advanced non-small cell lung cancer. It involves about 850 patients whose cancer has not been treated b…

This large Phase 3 trial is comparing a new drug combination against the current standard treatment for people newly diagnosed with follicular lymphoma, a type of blood cancer. About 733 participants will receive either the experimental drug odronextamab plus chemotherapy or the …

This study is testing two new antibody drugs, REGN9933 and REGN7508, to see if they can safely prevent dangerous blood clots in adults who need a PICC line catheter. About 195 participants will receive either one of the study drugs or a placebo. The main goals are to see if the d…

This study is testing an investigational drug called linvoseltamab in people diagnosed with high-risk smoldering multiple myeloma (SMM), a condition that often progresses to active multiple myeloma. The main goals are to see if the drug is safe and if it can eliminate the abnorma…

This study is gathering information, not testing a new treatment. It follows 11 men with Hemophilia B who are already receiving standard preventive therapy to stop bleeds. Researchers will track their bleeding events, therapy use, and quality of life for at least 6 months to bett…

This study is tracking the long-term health of 48 people with advanced skin cancer (melanoma) who previously received an experimental two-drug combination. No new treatment is given during this follow-up phase. Researchers are monitoring cancer status, overall health, and any add…

This is the first human study of an experimental drug called ALN-F1202, which targets a protein involved in blood clotting. The main goal is to check if the drug is safe and well-tolerated in 56 healthy volunteers. Researchers will give different single doses to see how the body …

This was an early, withdrawn study to check the safety and basic effects of an experimental drug called garetosmab in otherwise healthy adults with obesity. It aimed to see how the body processes the drug and how it might affect hormone levels and blood clotting. No participants …

This study follows 858 eczema patients who are starting treatment with Dupixent in real-world settings. Researchers will track how patients use the medication, monitor its effectiveness over time, and collect safety information. The goal is to understand how this treatment works …

This study is observing 718 asthma patients age 12 and older who are starting treatment with DUPIXENT® in real-world settings. Researchers will track who gets the treatment, how it's used, and how well it controls asthma and related conditions over three years. The goal is to gat…